Sign in Subscribe
Genetic research

NIH-Supported Gene-Editing Platform Lays Groundwork for Rapid Development of Treatments for Other Rare Genetic Diseases

Strategic Insights

— 2 min read

A research team supported by the National Institutes of Health (NIH) has developed and safely delivered a personalized gene editing therapy to treat an infant with a life-threatening, incurable genetic disease. The infant, who was diagnosed with the rare condition carbamoyl phosphate synthetase 1 (CPS1) deficiency shortly after birth, has responded positively to the treatment. The process, from diagnosis to treatment, took only six months and marks the first time the technology has been successfully deployed to treat a human patient.

Key Takeaways:

  • The NIH-supported research team developed and safely delivered a personalized gene editing therapy to treat an infant with CPS1 deficiency, a life-threatening genetic disease.
  • The treatment was administered using the gene-editing platform CRISPR, which enabled precise changes to DNA inside living cells.
  • The process, from diagnosis to treatment, took only six months, marking the first time the technology has been successfully deployed to treat a human patient.
  • The gene-editing platform developed by the researchers could be tweaked to treat a wide range of genetic disorders, opening the possibility of creating personalized treatments in other parts of the body.
  • The treatment required multiple administrations, with the infant initially receiving a low dose of the therapy and later receiving a higher dose.
  • The researchers observed signs of the treatment's effectiveness, including the infant's ability to consume more protein and reduce the medicine needed to keep ammonia levels low in the body.
  • The treatment was administered with caution, as the infant's condition made infections particularly dangerous, but the child was able to shrug off a cold and gastrointestinal illness.
  • The researchers are cautiously optimistic about the baby's progress, with much work remaining to be done.

Statistics:

  • 6 months: The time it took for the diagnosis to treatment process to be completed.
  • 1 infant: The number of patients treated using the personalized gene-editing therapy.
  • 1 gene mutation: The specific mutation in the baby's liver cells that was corrected using the CRISPR gene-editing platform.
  • 1 therapy administration: The first dose of the therapy administered to the infant.
  • $[X]: The amount of funding provided by the NIH Common Fund Somatic Cell Genome Editing program grants, U01TR005355, U19NS132301, U19NS132303, DP2CA281401, and National Heart, Lung, and Blood Institute grants R35HL145203 and P01HL142494.
  • 27 Institutes and Centers: The number of NIH Institutes and Centers, a component of the U.S. Department of Health and Human Services.
  • $[Y]: The amount of in-kind contributions made by Acuitas Therapeutics, Integrated DNA Technologies, Aldevron, and Danaher Corporation.

Sources:

  • Musunuru et al, "Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease." N Engl J Med. Online May 15, 2025. DOI: 10.1056/NEJMoa25re
  • NIH News Release, "NIH-supported gene-editing platform lays groundwork to rapidly develop treatments for other rare genetic diseases." May 15, 2025.

Read more